Reclassification of cannabis reflects systemic barriers to medical research and access
Original framing: “Trump administration reclassifies cannabis as less dangerous” — BBC News - World
Scientific evidence increasingly supports the medical benefits of cannabis for conditions such as chronic pain and epilepsy. However, the Schedule I status has severely limited clinical research, creating a gap between scientific consensus and regulatory practice.
The reclassification of cannabis is a symptom of a deeper systemic issue rooted in historical racism, corporate influence, and the exclusion of Indigenous and marginalized voices from policy-making.
To move forward, we must adopt a multi-dimensional approach that integrates scientific evidence, cultural wisdom, and restorative justice. This includes rescheduling cannabis for medical use, supporting community-led research, and implementing global policy exchanges. Only through such a holistic strategy can we dismantle the legacy of the War on Drugs and create a more just and equitable healthcare system.